Stichwort: CDK4/6 Inhibitors
![CDK4/6 inhibition in early breast cancer](https://www.abcsg.org/wp/wp-content/uploads/2023/08/CDK46-inhibition-in-early-b-280x189.jpg)
The on-demand video of the webinar „CDK4/6 inhibition in early breast cancer – Recent data and controversies?“ is now available!
22.11.2023
The virtual continuing education event “CDK4/6 inhibition in early breast cancer – Recent data and controversies?” took place on Wednesday, November 8th, 2023 (05:30 – 07:00 pm, CET). A total of 104 participants from 13 countries participated in the webinar.
weiter![CDK4/6 inhibition in early breast cancer](https://www.abcsg.org/wp/wp-content/uploads/2023/08/CDK46-inhibition-in-early-b-280x189.jpg)
CDK4/6 inhibition in early breast cancer – Recent data and controversies?
29.08.2023
Datum | 08.11.2023 |
Ort: | virtual |
In this international ABCSG webinar that is co-sponsored by EliLilly and Novartis we will present and discuss the most recent data of the pivotal adjuvant CDK4/6 studies monarchE and NATALEE.
weiter![Paradigm shift: a changing CDK4/6 inhibitor treatment landscape](https://www.abcsg.org/wp/wp-content/uploads/2023/07/CDK_4_6_ABCSG_Novartis_2023_wTEA-280x200.png)
Paradigm shift: a changing CDK4/6 inhibitor treatment landscape – NOW ONLINE!
12.07.2023
Datum | 14.09.2023 |
Ort: | virtual |
- CDK4/6 inhibitors – The big picture: what do we know so far?
- Earlier than ever: defining the role of adjuvant CDK4/6 inhibition
- Breaking new grounds: what’s next?
![Die ABCSG-Ergebnisse am ASCO 2022](https://www.abcsg.org/wp/wp-content/uploads/2022/06/Die-ABCSG-Ergebnisse-am-ASC-280x103.jpg)
Die ABCSG-Ergebnisse am ASCO 2022
10.06.2022
Wie angekündigt, wurde die Österreich am diesjährigen American Society of Clinical Oncology (ASCO) Meeting, das von 03.-07. Juni in Chicago stattfand, durch Univ.-Prof. Dr. Michael Gnant und Assoz. Prof. Priv.-Doz- Dr. Georg Pfeiler vertreten.
weiter![The Changing Treatment Landscape of CDK4/6 Inhibitors](https://www.abcsg.org/wp/wp-content/uploads/2022/04/CDK_4_6_Inhibitors_TEA_aun_1400x700_sRGB-280x140.jpg)
The Changing Treatment Landscape of CDK4/6 Inhibitors
Moving From Late to Early Stages – 09 May 2022
08.04.2022
Datum | May 09, 2022 |
Ort: | virtual |
Cyclin-dependent kinase (CDK) 4/6 inhibitors have emerged as an appealing targeted cancer therapy of patients with hormone receptor-positive breast cancer. Prior to the availability of CDK4/6 inhibitors, standard first-line therapy for patients with HR+/HER2- mBC was single-agent endocrine therapy.
weiter![CDK 4/6 Inhibitors: Nuance or Difference: 22 April 2021](https://www.abcsg.org/wp/wp-content/uploads/2021/03/CDK-46-Inhibitors-280x140.png)
CDK 4/6 Inhibitors: Nuance or Difference: 22 April 2021
02.03.2021
Datum | April 22, 2021 |
Ort: | virtual |
Cyclin-dependent kinase (CDK) 4/6 inhibitors are a new, yet meanwhile well-established class of therapeutic agents that improve the outcomes of patients with hormone receptor-positive breast cancer.
weiter![CDK4/6 Inhibitors](https://www.abcsg.org/wp/wp-content/uploads/2020/12/CDK_4_6_Inhib_SIG_pos_G-280x150.png)
CDK4/6 Inhibitors E-Learning
04.12.2020
Datum | 30.10.2020 |
Ort: | virtuell |
Der vergangene ESMO virtual Congress hat Highlights zum Thema CDK4/6-Inhibitoren auf den Plan gebracht, die von 4 ExpertInnen in einzelnen kurzen Video-Statements zusammengefasst wurden
weiterTeilen auf